{"id":"W4412442860","doi":"10.1016/j.jval.2025.04.1411","title":"PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bendamustine; Idelalisib; Chronic lymphocytic leukemia; Rituximab; Ibrutinib; Bruton's tyrosine kinase; Medicine; Ofatumumab; Internal medicine; Immunology; Oncology; Lymphoma; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001760785,0.001082698,0.001568814,0.000293786,0.0003188468,0.001182496,0.0008095565,0.0009814126,0.004458974],"category_scores_gemma":[0.001278652,0.0003726182,0.002186809,0.0003594907,0.0007054359,0.0007628589,0.0004501424,0.003032515,0.0007203337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001020425,"about_ca_system_score_gemma":0.000966159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009179697,"about_ca_topic_score_gemma":0.002338848,"domain_scores_codex":[0.9991533,0.0005008901,0.00003412804,0.0001122881,0.00006723213,0.0001321564],"domain_scores_gemma":[0.9991571,0.0002473643,0.0002295306,0.00004830824,0.00004450732,0.0002732446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.881861,0.006579661,0.00664887,0.001027321,0.003811629,0.0001007948,0.0001184906,0.002277496,0.009001142,0.000293881,0.004059937,0.08421975],"study_design_scores_gemma":[0.7748388,0.1807239,0.03235413,0.0001745436,0.003236808,0.0002799793,0.0001146822,0.002312852,0.001665792,0.0005375698,0.003694219,0.00006677928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890121,0.005587989,0.0002893346,0.0006055371,0.0001629859,0.0004419895,0.00149805,0.00008075576,0.002321294],"genre_scores_gemma":[0.9906991,0.002303512,0.0007445635,0.0007614066,0.00020582,0.0008276767,0.002533863,0.00002691282,0.001896993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004458974,"threshold_uncertainty_score":0.01491672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07727139236211535,"score_gpt":0.3782010551301899,"score_spread":0.3009296627680746,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}